Page 492«..1020..491492493494..500510..»

ARCA biopharma Establishes Special Committee of the Board of Directors

Posted: April 19, 2022 at 1:52 am

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value.   The Company believes there are multiple potential opportunities to enhance value for ARCA stockholders. The Special Committee includes ARCA Board Chairman Robert E. Conway (chair), and Board members Linda Grais, M.D. and Anders Hove, M.D.

More here:
ARCA biopharma Establishes Special Committee of the Board of Directors

Posted in Global News Feed | Comments Off on ARCA biopharma Establishes Special Committee of the Board of Directors

Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

Posted: April 19, 2022 at 1:52 am

PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will present at the virtual Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 25, 2022, at 9:30 AM ET.

Follow this link:
Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

Posted in Global News Feed | Comments Off on Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

Posted: April 19, 2022 at 1:52 am

ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now be offering 50% more doses for patient use Monday-Friday beginning the week of May 1, 2022.

The rest is here:
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

Posted in Global News Feed | Comments Off on Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

Minnesota woman reunites with teenager she saved through Be The Match transplant – KSTP

Posted: April 19, 2022 at 1:52 am

Every year, more than 18,000 patients search the Be The Match registry hoping to connect with someone who can provide a life-saving donation. The organization locates blood stem-cell or bone marrow transplants for patients with blood cancer or disease.

Matches are found across the country and the world.

I didnt think anything was going to come of it, said donor Haven Davis of Minneapolis.

The teacher added her name to the registry in 2017 after hearing a podcast about the life-saving program. Once someone signs up to be a donor, the organization sends a kit in the mail and the donor provides a cheek swab. The DNA sample is then analyzed.

I think it was less than two months later that I got a phone call I had matched, said Davis. It was just kind of hard to believe.

Be The Match provided limited details about the person who would receive of her donation, including the age and diagnosis.

When I found out that she was only 14, that was when I was really convinced, she said. How can I not help this teenager who needs this?

The 14-year-old patient was Gwen Cinquemani, who lived more than a thousand miles away in New Rochelle, New York. Her life had recently been upended by an MDS diagnoses. Its a rare disorder that affects the bodys red blood cell supply.

I was very active, I had just made the JV cheer team, she told us. The diagnosis kind of halted everything so fast. I went from what felt like everything to nothing.

Prior to her diagnosis, Tiffany Cinquemani noticed her daughter seemed more tired and bruised more easily than normal. Blood work at an annual appointment confirmed she wasnt well.

Your whole world stops, said Tiffany Cinquemani. You get a call from the doctor and youre basically told get your daughter to the hospital immediately so you know its not good. We took her there, and you know, after a series of tests they diagnosed her with MDA and it was terrible. Theres nothing worse.

She added, It was very scary. I mean obviously I knew something was wrong but had no idea how serious it really was.

Doctors determined Gwen needed a bone marrow transplant. Despite being a triplet, her brothers werent a match. In Minneapolis, Davis answered the call.

It really didnt feel like a difficult process or a difficult decision, Davis said.

In November 2018, Davis had a surgical procedure to extract bone marrow from her hip. She went home from the hospital on the same day.

In New York, Gwens recovery from the transplant took longer.

It took two days to get the cells, the teenager explained. Its given to you like a blood transfusion so you just kind of wait for it all to go in. Its done really precisely where the nurses and doctors are kind of timing how fast it goes into you.

Gwen stayed in the hospital until her body started making its own blood cells. After 56 days, she went home. The procedure was successful.

About a year and a half later, the teenager was able to connect with Davis through e-mail.

Before I even opened the email, I could see it said Thank you for saving our daughters life, said Davis. I think that was the moment I realized how impactful this whole situation was.

They stayed in touch during the pandemic, sharing life updates. Last Thursday, they finally met in-person at the Be The Match Gala in New York City.

It was surreal, said Tiffany Cinquemani. It was just amazing to meet the person who saved her life and shes just a wonderful person.

The family embraced Davis on stage.

I think my biggest takeaway from the entire experience has just been a feeling of gratitude, said Davis. I feel really grateful to have such a beautiful connection with such a great family.

The moment also highlighted Gwens progress.

I can go to school, cheer practice hang out with my friends, said Gwen, who is now 16-years-old. Id say Im fully healthy now.

Doctors will monitor her closely for five years post-transplant. She explained she still sees a hematologist every couple of months to track her progress.

Be The Match estimates about only 25 to 30 percent of patients have a family member who can provide a donation. Last year, the organization facilitated about 6,600 transplants.

We need people to join the registry, said Joy King, the chief advancement officer. We need young people to join the registry because the younger you are, the healthier your cells are that create blood that the patient needs. We also need individuals that are ethnically diverse to join the registry as well so we can make sure that all of our patients have equal outcomes.

King explained its critical that donors follow through once they start the process as well.

For many patients, their journey to receive a blood stem cell or bone marrow transplant is their only chance at cure, she said. Its really important people follow through and once you say yes, and start your process to donate to a patient, that you dont back out. Thats because patients start regiment a treatment regimen that absolutely gets rid of their immune system and we need that to fight off disease. Its can be life-threatening if that donation process doesnt match up with the timing that the patient needs to receive those lifesaving cells.

If you are interested in joining the Be The Match registry, click here.

Read more here:
Minnesota woman reunites with teenager she saved through Be The Match transplant - KSTP

Posted in Minnesota Stem Cells | Comments Off on Minnesota woman reunites with teenager she saved through Be The Match transplant – KSTP

Oral Cavity | histology – University of Michigan

Posted: April 19, 2022 at 1:52 am

1. Lining Mucosa

Slide 114R (lip, human, H&E) View Virtual Slide Slide 114 triC (lip, human, trichrome) View Virtual SlideSlide 114M (lip, monkey, H&E) View Virtual Slide

A stratified squamous non-keratinized epithelium lines the oral surface of the lips, cheeks, floor of mouth, and covers the ventral surface of the tongue In slide 114 (human) and 114M (monkey) of the lip, note that skin (stratified, keratinized squamous epithelium with hair follicles) covers the external surface View Image, skeletal muscle (orbicularis oris muscle) forms the core View Image, and a mucosal epithelium(stratified, non-keratinizing squamous epithelium) covers the internal surface View Image. A lamina propria underlies the mucosa and small salivary glands (labial salivary glands) View Image are present in the submucosa. Note the transition zone between the keratinized epithelium of the skin and the nonkeratinized epithelium of the mucosa. This transition zone is called the vermillion zone(present only in humans) View Image. In the transition zone, long connective tissue papillae extend deep into the epithelium. Capillaries are carried close to the surface in these papillae. Because the epithelium is very thin in this region, the lips appear red (this arrangement may or may not be apparent in your glass slides). Salivary glands are lacking in the vermillion zone, therefore, the lips must be continuously moistened (by the tongue) to prevent drying out.

Slide 115 (fetal palate, H&E) View Virtual SlideSlide 115 (fetal palate, trichrome) View Virtual Slide

A stratified squamous keratinized epithelium is found on surfaces subject to the abrasion that occurs with mastication, e.g., the roof of the mouth (palate) and gums (gingiva). Slide 115, which you used to study bone and the respiratory system, is a longitudinal section through the palate and includes the lip, gingiva, hard palate, and a portion of the soft palate [orientation]. This tissue is from a term fetus (with unerrupted teeth) and the epithelium over the hard palate is not yet fully differentiated (i.e. not fully keratinized). The slide is, however, a good overall orientation to the histology of the hard and soft palate. In the adult the epithelium of the hard palate is keratinized. Identify respiratory epithelium, bone (hard palate), forming tooth View Image, and skeletal muscle in the lipView Image and the soft palate View Image. Some slides show mucous salivary glands View Image in the submucosa.

Slide 116 40x (tongue, H&E) View Virtual SlideSlide 117 20x (tongue, H&E) View Virtual SlideSlide 117 40x (tongue, H&E) View Virtual SlideSlide 117N 40x (tongue, rabbit, H&E) View Virtual Slide

The dorsal surface and lateral borders of the tongue are covered by a mucous membrane that contains nerve endings for general sensory reception and taste perception. In slide 116, the dorsal surface of the tongue is covered with tiny projections called papillae View Image, which are lacking on the ventral surface. The body of the tongue is composed of interlacing bundles of skeletal muscle View Image that cross one another at right angles. The dense lamina propria of the mucosa is continuous with the connective tissue of the muscle, tightly binding the mucous membrane to the muscle. Some glass slides in our collection show mucous glands in the submucosa, which are found only on the ventral side of the tongue. These glands are not present in the digital slides, but their ducts may be seen View Image.

In slide 116 there are two types of papillae on the tongue. Locate the numerous filiform papillae View Image, that appear as conical structures with a core of lamina propria covered by a keratinized epithelium. Fungiform papillae View Image are scattered among the filiform papillae. They have expanded smooth round tops and narrower bases. In young children, the fungiform papillae can be seen with the naked eye as red spots on the dorsum of the tongue (because the non-keratinized epithelium is relatively translucent). These papillae are less readily observed in adults, because of slight keratinization of the epithelium.

Slide 117 and especially slide 117N contain examples of circumvallate papillaeView Image. These are large circular papillae surrounded by a deep trench. The covering epithelium is non-keratinized. Taste budsView Image, the chemoreceptors for the sense of taste, are located on the lateral borders. Each taste bud contains about 50 spindle shaped cells that are classically described based on their appearance as light (receptor) cells, dark (supporting) cells, and basal (stem) cells, although these distinctions are difficult to see in your slides so we do not require you to identify the cell types. Non-myelinated nerves from cranial nerves VII, IX, or X (depending on the location of the taste bud) synapse with the receptor and, to some extent, supporting cells of the taste bud. Some slides show serous glands (of von Ebner) View Image in the lamina propria and interspersed between the bundles of muscle beneath the papillae. These glands drain into the base of the trench around the circumvallate papillae.

See the original post here:
Oral Cavity | histology - University of Michigan

Posted in Michigan Stem Cells | Comments Off on Oral Cavity | histology – University of Michigan

Unraveling Stem Cells’ Secrets: Immortality of Germline Cells and the Function of Junk DNA – SciTechDaily

Posted: April 19, 2022 at 1:52 am

MIT biology professor Yukiko Yamashita has spent much of her career exploring how asymmetrical cell divisions occur. This type of cell division allows cells to differentiate into different types of tissue, and also helps germline cells such as eggs and sperm to maintain their viability from generation to generation. Credit: M. Scott Brauer

The MIT biologist Yukiko Yamashitas research has shed light on the immortality of germline cells and the function of junk DNA.

When cells divide, they usually generate two identical daughter cells. However, there are some important exceptions to this rule: When stem cells divide, they often produce one differentiated cell along with another stem cell, to maintain the pool of stem cells.

Yukiko Yamashita has spent much of her career exploring how these asymmetrical cell divisions occur. These processes are critically important not only for cells to develop into different types of tissue, but also for germline cells such as eggs and sperm to maintain their viability from generation to generation.

We came from our parents germ cells, who used to be also single cells who came from the germ cells of their parents, who used to be single cells that came from their parents, and so on. That means our existence can be tracked through the history of multicellular life, Yamashita says. How germ cells manage to not go extinct, while our somatic cells cannot last that long, is a fascinating question.

Yamashita, who began her faculty career at the University of Michigan, joined MIT and the Whitehead Institute in 2020, as the inaugural holder of the Susan Lindquist Chair for Women in Science and a professor in the Department of Biology. She was drawn to MIT, she says, by the eagerness to explore new ideas that she found among other scientists.

When I visited MIT, I really enjoyed talking to people here, she says. They are very curious, and they are very open to unconventional ideas. I realized I would have a lot of fun if I came here.

By studying fruit flies, Yukiko Yamashita has discovered the function of DNA segments that were previously thought to be junk. Credit: MIT

Before she even knew what a scientist was, Yamashita knew that she wanted to be one.

My father was an admirer of Albert Einstein, so because of that, I grew up thinking that the pursuit of the truth is the best thing you could do with your life, she recalls. At the age of 2 or 3, I didnt know there was such a thing as a professor, or such a thing as a scientist, but I thought doing science was probably the coolest thing I could do.

Yamashita majored in biology at Kyoto University and then stayed to pursue her PhD, studying how cells make exact copies of themselves when they divide. As a postdoc at Stanford University, she became interested in the exceptions to that carefully orchestrated process, and began to study how cells undergo divisions that produce daughter cells that are not identical. This kind of asymmetric division is critical for multicellular organisms, which begin life as a single cell that eventually differentiates into many types of tissue.

Those studies led to a discovery that helped to overturn previous theories about the role of so-called junk DNA. These sequences, which make up most of the genome, were thought to be essentially useless because they dont code for any proteins. To Yamashita, it seemed paradoxical that cells would carry so much DNA that wasnt serving any purpose.

I couldnt really believe that huge amount of our DNA is junk, because every time a cell divides, it still has the burden of replicating that junk, she says. So, my lab started studying the function of that junk, and then we realized it is a really important part of the chromosome.

When I visited MIT, I really enjoyed talking to people here, Yamashita says. They are very curious, and they are very open to unconventional ideas. I realized I would have a lot of fun if I came here. Credit: M. Scott Brauer

In human cells, the genome is stored on 23 pairs of chromosomes. Keeping all of those chromosomes together is critical to cells ability to copy genes when they are needed. Over several years, Yamashita and her colleagues at the University of Michigan, and then at MIT, discovered that stretches of junk DNA act like bar codes, labeling each chromosome and helping them bind to proteins that bundle chromosomes together within the cell nucleus.

Without those barcodes, chromosomes scatter and start to leak out of the cells nucleus. Another intriguing observation regarding these stretches of junk DNA was that they have much greater variability between different species than protein-coding regions of DNA. By crossing two different species of fruit flies, Yamashita showed that in cells of the hybrid offspring flies, chromosomes leak out just as they would if they lost their barcodes, suggesting that the codes are specific to each species.

We think that might be one of the big reasons why different species become incompatible, because they dont have the right information to bundle all of their chromosomes together into one place, Yamashita says.

Yamashitas interest in stem cells also led her to study how germline cells (the cells that give rise to eggs and sperm cells) maintain their viability so much longer than regular body cells across generations. In typical animal cells, one factor that contributes to age-related decline is loss of genetic sequences that encode genes that cells use continuously, such as genes for ribosomal RNAs.

A typical human cell may have hundreds of copies of these critical genes, but as cells age, they lose some of them. For germline cells, this can be detrimental because if the numbers get too low, the cells can no longer form viable daughter cells.

Yamashita and her colleagues found that germline cells overcome this by tearing sections of DNA out of one daughter cell during cell division and transferring them to the other daughter cell. That way, one daughter cell has the full complement of those genes restored, while the other cell is sacrificed.

That wasteful strategy would likely be too extravagant to work for all cells in the body, but for the small population of germline cells, the tradeoff is worthwhile, Yamashita says.

If skin cells did that kind of thing, where every time you make one cell, you are essentially trashing the other one, you couldnt afford it. You would be wasting too many resources, she says. Germ cells are not critical for viability of an organism. You have the luxury to put many resources into them but then let only half of the cells recover.

Read more here:
Unraveling Stem Cells' Secrets: Immortality of Germline Cells and the Function of Junk DNA - SciTechDaily

Posted in Michigan Stem Cells | Comments Off on Unraveling Stem Cells’ Secrets: Immortality of Germline Cells and the Function of Junk DNA – SciTechDaily

Scientists De-Aged a Woman’s Skin Cells by 30 Years – The Daily Beast

Posted: April 19, 2022 at 1:52 am

While the Fountain of Youth is the stuff of legend, the search for a way to stop humans from aging is happening as we speakinside the laboratory.

In a study published in the journal eLife on April 8, scientists at Babraham Institute in the U.K. managed to de-age the skin cells of a 53-year-old woman by 30 years in a petri dish. Looking at age-related biological changes in the DNA, these genetically-modified younger cells appeared and behaved as any 23-year-old skin cell should. Notably, the team was also able to de-age the cells in less than two weeks.

The techniques used in this experiment have been around for the last few decades. However, with the woman's skin cells, the researchers managed to shave off time from the usually long process while also avoiding the problems reprogrammed cells can often run into, like inadvertently turning cancerous.

This kind of work is very important, Dr. Ivona Percec, a plastic surgeon and stem cell researcher at the University of Pennsylvania School of Medicine, who was not involved in the study, told The Daily Beast. And its one thats been sought out by many scientists in order to reverse or delay aging.

Most rejuvenation or regeneration research makes use of human stem cells, which have the unique ability to develop into any other type of cell our body needs, such as muscle and brain cells. Stem cells can also renew themselves over time and serve as an internal repair system, replacing lost or damaged cells during a persons lifetime. But stem cells are quite difficult to produce in the laband are often rejected by the body when used in different types of therapies.

To get around these hurdles, scientists have been creating their own lab-grown stem cells called induced pluripotent stem cells (iPSCs). They are created by taking any cell in our body and genetically editing it to resemble an embryonic stem cell, George Sen, a molecular biologist at the University of California San Diego who was not involved in the study, told The Daily Beast in an email.

To make their iPSCs, the Babraham researchers reversed the cellular clock on their 53-year-old skin cells by bathing them in a chemical solution that encourages the growth of proteins that reshape a cells DNA. To control how far they de-age the cells, the researchers allowed the bath to run for a little less than two weeks than the typical 50 days. Then they assessed the age of the skin cells by looking for age-related biological changes.

I remember the day I got the results back and I didn't quite believe that some of the cells were 30 years younger than they were supposed to be, Dilgeet Gill, a biomedical researcher at Babraham Institute and lead author of the study, told the BBC. It was a very exciting day!"

Young fibroblasts in the first image. The next two images are after 10 days, right with treatment. The last two images are after 13 days, right with treatment. Red shows collagen production which has been restored.

Ftima Santos

These newly minted young skin cells, called fibroblasts, produce collagen, which is a protein responsible for healthy joints and elastic skin throughout the body. When researchers cut through the cell layer (like how if you injure your skin), the fibroblasts moved into the gash quickly to fill it, unlike the older cells.

Though the findings are quite encouraging, were still some ways from seeing this new de-aging technique used in a clinical setting. Experts also have some lingering questions regarding how long exactly this rejuvenation lasts and whether the new technique actually improves a cells lifespan.

The authors only looked for a short period of time after [applying Yamanaka factors] but what happens once the cell has divided a few times? Does the molecular clock catch up? asked Sen. The authors also never tested whether the de-aged fibroblasts behaved as younger fibroblasts in live animal models. This question would need to be addressed before this can be used as therapy.

Whether this is the key to the Fountain of Youth remains to be seen.

Dr. Johann Gudjonsson, University of Michigan

Dr. Johann Gudjonsson, a dermatologist who studies inflammatory skin conditions at The University of Michigan and wasn't involved in the study, is also skeptical of the experiment.

Whether this is the key to the Fountain of Youth remains to be seen, Gudjonsson told The Daily Beast in an email. He explained that telomeres, which are the caps binding the ends of DNA and shorten as we age, didnt appear to improve with the new studys treatment. Therefore while the function and state of the cells are rejuvenated it may not mean that their lifespan has changed, he said.

Even if longevity and immediate clinical applications arent in the cards, this new study does offer an interesting proof of concept for future medical research and potentially combating aging.

If this process can be applied to other cell types, one can imagine rejuvenating that particular cell type and using it to restore an aged/failing organ, said Sen. I believe this line of research has a lot of potential and we are just starting to understand the rules of how to reprogram cells.

More here:
Scientists De-Aged a Woman's Skin Cells by 30 Years - The Daily Beast

Posted in Michigan Stem Cells | Comments Off on Scientists De-Aged a Woman’s Skin Cells by 30 Years – The Daily Beast

CAR T-cell therapy currently in UC Davis Health clinical trial study as potential cure for HIV – The Aggie – The Aggie

Posted: April 19, 2022 at 1:50 am

CAR T-cell immunotherapy may become the alternative option to current life-long retroviral therapy for HIV patients

By BRANDON NGUYEN science@theaggie.org

According to the Joint United Nations Programme on AIDS/HIV or UNAIDS, around 38 million people worldwide live with HIV, a retrovirus that destroys a hosts own immune cells and can progress into AIDS if left untreated. To put this into perspective, around 150,000 people are living with HIV but 68% of them are virally suppressed due to adherence to life-long retroviral therapy.

In efforts to search for an alternative option to life-long treatment, UC Davis Health has commenced a study testing the efficacy of Chimeric Antigen Receptor T-cell Therapy (CAR T-cell Therapy) and its potential as a cure for HIV. CAR T-cell therapy involves the removal of a patients immune systems T-cells and genetically modifying them to recognize and attack HIV-afflicted cells in the host.

Dr. Mehrdad Abedi, a professor of internal medicine, hematology and oncology at UC Davis Health and the principal investigator of the study, further explained the process in administering CAR T-cell therapy to a patient.

For this study, we will educate the cells by inserting a gene to target cells that have been infected by the HIV virus, Abedi said. The idea is these modified cells will attach to the HIV-infected cells and destroy the cells that are infected while also stopping the infected cells ability to replicate.

Modification of human patient T-cells into CAR T-cells has revolutionized patient care, especially for cancer patients. This technology has become widely used in the field of oncology and blood cancer patients, as training ones T-cells to recognize tumors from normal, healthy cells is a novel method to search and destroy tumor cells throughout the blood. This would be impossible with radiation or surgery.

Dr. Paolo Troia-Cancio, a clinical professor of medicine with the infectious disease division and co-investigator for the HIV study, described how the study came about as a result of success stories of patients with HIV and cancer.

It has been shown to be possible to cure HIV because so far there have been three individuals that have been cured of HIV, but they have required bone marrow transplants, Troia-Cancio said. Two of the three patients were administered more conventional allergenic bone marrow transplants and the third person got a transplant from cord blood stem cells. I hope with this type of research that we take what we have learned from these three individuals and apply them in a way that we could modify a patients immune system in a way to make it resistant to HIV.

However, bone marrow transplants are not the ideal or first option for patients with HIV.

While these stories provide inspiration and hope to finding a cure for HIV, a bone marrow transplant is not a realistic option for most patients, Abedi said. Such transplants are highly invasive and risky, so they are generally offered only to people with cancer who have exhausted all other options.

Nonetheless, these three fortunate cases offer hope for a cure, or at least a functional cure, which Troia-Cancio explained as patients being able to control their HIV without medication. With an optimistic outlook for HIV patients, Troia-Cancio underscored the potential for CAR T-cell therapy to revolutionize the healthcare industry in treating other immunological disorders.

There are other diseases where CAR T-cells are being looked at, Troia-Cancio said. So I think theres a potential for this therapy to become more widely used for other areas where having essentially a modified immune system could potentially lead to either long term control or omission or even a cure for a disease.

Written by: Brandon Nguyen science@theaggie.org

Read the original post:
CAR T-cell therapy currently in UC Davis Health clinical trial study as potential cure for HIV - The Aggie - The Aggie

Posted in Cell Therapy | Comments Off on CAR T-cell therapy currently in UC Davis Health clinical trial study as potential cure for HIV – The Aggie – The Aggie

Aurion $120m to advance cell therapy candidate – BioProcess Insider – BioProcess Insider

Posted: April 19, 2022 at 1:50 am

The funding will be used to develop Aurion Biotechs first candidate, AURN001, a cell therapy aiming to treat corneal edema.

Aurion Biotech is a clinical-stage biotech firm that is aiming to restore vision to millions of patients with its regenerative therapies. According to the firm, the raised funds will be used to file an IND to the US Food and Drug Administration (FDA) in order to begin clinical trials.

Additionally, Aurion wants to submit an NDA to the Japan Pharmaceuticals and Medical Devices Agency (PMDA).

Image: Stock Photo Secrets

Funds will be used to advance the clinical development of our cell therapy for corneal edema [AURN001], secondary to corneal endothelial disease, Judith McGarry, vice president marketing at Aurion told BioProcess Insider.

The endothelium is a single layer of cells in the human cornea; it regulates hydration of the cornea. When those cells degrade or die (due to disease or surgical trauma), they do not regenerate. Once those cells are gone, the cornea become swollen and cloudy, ultimately causing loss of vision.

The cell therapy was developed by Shigeru Kinoshita and his colleagues at Kyoto Prefecture University of Medicine (KPUM) in Japan. Aurion acquired this technology in 2020 and is preparing to submit a Japanese new drug application (J-NDA).

First, our inventor was able to figure out how to get human corneal endothelial cells (HCECs) to replicate in the lab (keep in mind, they do not replicate in the body). With this patented process, the cells from a single donor can be manufactured to treat up to 100 eyes, said McGarry.

She continued: This alone is a significant benefit since there is a global shortage of donor corneas available for transplant. Second, the cell therapy procedure itself is relatively straightforward, and can be performed in an outpatient setting, in approximately 15 minutes. The ophthalmologist makes an incision into the anterior chamber of the patients eye, and polishes off the diseased endothelial cells. Then, via another incision, the ophthalmologist injects HCECs in solution into the anterior chamber. The cells quickly settle into place, along the stroma of the cornea [and] the patient lies face down for a couple of hours, to facilitate adhesion.

The $120 million financing was led by Deerfield Management, and included current investors Flying L Partners, Falcon Vision, KKR, Visionary Ventures, and Petrichor Healthcare Capital Management. Furthermore, funds will be paid out to Aurion based on specific achievements of clinical and operational milestones.

Original post:
Aurion $120m to advance cell therapy candidate - BioProcess Insider - BioProcess Insider

Posted in Cell Therapy | Comments Off on Aurion $120m to advance cell therapy candidate – BioProcess Insider – BioProcess Insider

ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients – BioSpace

Posted: April 19, 2022 at 1:50 am

MONTREAL, April 13, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today the publication of a scientific article entitled UM171 expansion of cord blood improves donor availability and HLA matching for all patients, including minorities. The study by Dumont-Lagac et al., was recently published in the peer-reviewed medical journal Transplantation and Cellular Therapy.

Using data from the Be The Match donor and cord blood registry, the retrospective study concluded that expansion with UM171:

UM171 is the proprietary molecule used in ExCellTheras lead technology, ECT-001, a cell therapy under development being evaluated in several clinical trials in the United States and Canada.

A persistent problem under the current standard of care for allogeneic stem cell transplantation is finding a suitable donor for all patients. While cord blood units cryopreserved in public banks offer a readily available source of stem cells for transplantation, the low number of cells they contain have hampered their use. This new study demonstrates how expanding small cord blood units results in a greater access to transplantation.

The results of this study are supported by what we have seen in our clinical trials, where weve been able to identify a cord suitable for expansion for all patients enrolled, no matter their ethnic origin, said Dr. Pierre Caudrelier, Chief Medical Officer of ExCellThera. Furthermore, thanks to the low starting cell dose requirement for UM171 expanded grafts, about half of the patients in our first Phase I/II trial benefited from better HLA matching than would have been possible without expansion.

About ExCellThera Inc.

ExCellThera is a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellTheras most advanced technology, ECT-001, a cell therapy, combines a proprietary molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its cell expansion and engineering platform, as well as supporting best-in-class clinical trials. excellthera.com

Follow this link:
ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients - BioSpace

Posted in Cell Therapy | Comments Off on ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients – BioSpace

Page 492«..1020..491492493494..500510..»